Polyp Size Measurement at CT Colonography: What Do We Know and What Do We Need to Know?

被引:55
|
作者
Summers, Ronald M. [1 ]
机构
[1] NIH, Imaging Biomarkers & Comp Aided Diag Lab, Dept Radiol & Imaging Sci, Ctr Clin, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
COMPUTED TOMOGRAPHIC COLONOGRAPHY; COLONIC POLYPS; COLORECTAL-CANCER; VIRTUAL COLONOSCOPY; HYPERPLASTIC POLYPS; NATURAL-HISTORY; IN-VITRO; AUTOMATED MEASUREMENT; AMERICAN-COLLEGE; NATIONAL POLYP;
D O I
10.1148/radiol.10090877
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Polyp size is a critical biomarker for clinical management. Larger polyps have a greater likelihood of being or of becoming an adenocarcinoma. To balance the referral rate for polypectomy against the risk of leaving potential cancers in situ, sizes of 6 and 10 mm are increasingly being discussed as critical thresholds for clinical decision making (immediate polypectomy versus polyp surveillance) and have been incorporated into the consensus CT Colonography Reporting and Data System (C-RADS). Polyp size measurement at optical colonoscopy, pathologic examination, and computed tomographic (CT) colonography has been studied extensively but the reported precision, accuracy, and relative sizes have been highly variable. Sizes measured at CT colonography tend to lie between those measured at optical colonoscopy and pathologic evaluation. The size measurements are subject to a variety of sources of error associated with image acquisition, display, and interpretation, such as partial volume averaging, two-versus three-dimensional displays, and observer variability. This review summarizes current best practices for polyp size measurement, describes the role of automated size measurement software, discusses how to manage the measurement uncertainties, and identifies areas requiring further research.
引用
收藏
页码:707 / 720
页数:14
相关论文
共 50 条
  • [21] Cryptococcus escapes host immunity: What do we know?
    Yang, Chen
    Huang, Yemei
    Zhou, Yangyu
    Zang, Xuelei
    Deng, Hengyu
    Liu, Yitong
    Shen, Dingxia
    Xue, Xinying
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [22] Nutrition and Cancer Prevention: What do we know today?
    Giessen, Hannelore
    Kerschbaum, Eva
    Hauner, Dagmar
    Hauner, Hans
    ERNAHRUNGS UMSCHAU, 2021, 68 (03): : M150 - M157
  • [23] The early pregnancy in mares - What do we still not know?
    Siemieniuch-Tartanus, Marta
    VETERINARY AND ANIMAL SCIENCE, 2025, 28
  • [24] Tooth agenesis: What do we know and is there a connection to cancer?
    Bonczek, Ondrej
    Krejci, Premysl
    Izakovicova-Holla, Lydie
    Cernochova, Pavlina
    Kiss, Igor
    Vojtesek, Borivoj
    CLINICAL GENETICS, 2021, 99 (04) : 493 - 502
  • [25] Pleomorphic xanthoastrocytoma -: What do we really know about it?
    Giannini, C
    Scheithauer, BW
    Burger, PC
    Brat, DJ
    Wollan, PC
    Lach, B
    O'Neill, BP
    CANCER, 1999, 85 (09) : 2033 - 2045
  • [26] What we know and still do not know about tick-borne encephalitis?
    Kriha, M. F.
    Chrdle, A.
    Ruzek, D.
    Chmelik, V
    EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE, 2021, 70 (03): : 189 - 198
  • [27] Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know?
    Pfab, Christina
    Schnobrich, Luisa
    Eldnasoury, Samir
    Gessner, Andre
    El-Najjar, Nahed
    CANCERS, 2021, 13 (13)
  • [28] Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
    Pinheiro, Ruben G. R.
    Coutinho, Ana Joyce
    Pinheiro, Marina
    Neves, Ana Rute
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [29] Platelet Storage Lesions: What More Do We Know Now?
    Ng, Monica Suet Ying
    Tung, John-Paul
    Fraser, John Francis
    TRANSFUSION MEDICINE REVIEWS, 2018, 32 (03) : 144 - 154
  • [30] Diet, nutrition, and cancer risk: what do we know and what is the way forward?
    Key, Timothy J.
    Bradbury, Kathryn E.
    Perez-Cornago, Aurora
    Sinha, Rashmi
    Tsilidis, Konstantinos K.
    Tsugane, Shoichiro
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 368